CY1117638T1 - Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης - Google Patents

Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης

Info

Publication number
CY1117638T1
CY1117638T1 CY20161100527T CY161100527T CY1117638T1 CY 1117638 T1 CY1117638 T1 CY 1117638T1 CY 20161100527 T CY20161100527 T CY 20161100527T CY 161100527 T CY161100527 T CY 161100527T CY 1117638 T1 CY1117638 T1 CY 1117638T1
Authority
CY
Cyprus
Prior art keywords
triazol
picolinamide
benzamide
derivatives
antagonists
Prior art date
Application number
CY20161100527T
Other languages
English (en)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1117638T1 publication Critical patent/CY1117638T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με παράγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδίου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιν-αμιδίου με τον τύπο (I) Τύπος (I) όπου τα Ar1, Q, R1 έως R5 είναι όπως περιγράφονται στην περιγραφή, με την παρασκευή τους, με τα φαρμακευτικώς αποδεκτά άλατα τους και με τη χρήση τους ως φάρμακα, με φαρμακευτικές συνθέσεις οι οποίες περιέχουν μία ή περισσότερες ενώσεις με τον τύπο (I), και ιδίως με τη χρήση τους ως ανταγωνιστές του υποδοχέα της ορεξίνης.
CY20161100527T 2011-11-08 2016-06-15 Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης CY1117638T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08
EP12791862.1A EP2776430B1 (en) 2011-11-08 2012-11-07 2- (1,2,3-triazol-2-yl) benzamide and 3-(1,2,3-triazol-2-yl) picolinamide derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
CY1117638T1 true CY1117638T1 (el) 2017-04-26

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100527T CY1117638T1 (el) 2011-11-08 2016-06-15 Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης

Country Status (28)

Country Link
US (1) US9150566B2 (el)
EP (1) EP2776430B1 (el)
JP (1) JP5718535B2 (el)
KR (1) KR101676930B1 (el)
CN (1) CN103917538B (el)
AR (1) AR088692A1 (el)
AU (1) AU2012335194B2 (el)
BR (1) BR112014010617B1 (el)
CA (1) CA2846568C (el)
CL (1) CL2014000659A1 (el)
CY (1) CY1117638T1 (el)
DK (1) DK2776430T3 (el)
EA (1) EA024106B1 (el)
ES (1) ES2572703T3 (el)
HK (1) HK1199022A1 (el)
HR (1) HRP20160678T1 (el)
HU (1) HUE029239T2 (el)
IL (1) IL232462A (el)
IN (1) IN2014CN04127A (el)
MX (1) MX343837B (el)
MY (1) MY167791A (el)
PL (1) PL2776430T3 (el)
SG (1) SG11201401665WA (el)
SI (1) SI2776430T1 (el)
TW (2) TWI555747B (el)
UA (1) UA112317C2 (el)
WO (1) WO2013068935A1 (el)
ZA (1) ZA201404189B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
CA2929423C (en) 2013-12-03 2021-12-07 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1 ,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
JP5907310B2 (ja) * 2013-12-13 2016-04-26 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
EP3143999A4 (en) 2014-05-16 2017-12-20 The University of Tokyo Depression treatment agent
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
CN109219606B (zh) 2016-02-12 2021-10-01 阿斯利康(瑞典)有限公司 食欲素受体调节剂的卤素取代的哌啶
MX2019012902A (es) 2017-05-03 2019-12-16 Idorsia Pharmaceuticals Ltd Preparacion de derivados de acido 2-([1,2,3]triazol-2-il)-benzoico .
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
TW202241447A (zh) 2021-02-02 2022-11-01 瑞士商愛杜西亞製藥有限公司 (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-嗎啉-4-基]-甲酮之結晶形式
AR129309A1 (es) * 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
US20040192673A1 (en) * 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
EP1399441B1 (en) * 2001-06-28 2006-07-05 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2005250077B2 (en) 2004-03-01 2011-06-09 Idorsia Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2739915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739917A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5847087B2 (ja) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ.ベー. オレキシン受容体調節因子としての縮合複素環式化合物

Also Published As

Publication number Publication date
ES2572703T3 (es) 2016-06-01
JP2014532753A (ja) 2014-12-08
BR112014010617A2 (pt) 2017-04-25
HUE029239T2 (en) 2017-02-28
PL2776430T3 (pl) 2016-09-30
IL232462A (en) 2016-11-30
IN2014CN04127A (el) 2015-07-10
KR20140096338A (ko) 2014-08-05
ZA201404189B (en) 2017-08-30
US20150158855A1 (en) 2015-06-11
DK2776430T3 (en) 2016-05-09
EP2776430A1 (en) 2014-09-17
CA2846568A1 (en) 2013-05-16
CL2014000659A1 (es) 2014-08-18
MX343837B (es) 2016-11-24
TW201632517A (zh) 2016-09-16
IL232462A0 (en) 2014-06-30
HK1199022A1 (zh) 2015-06-19
SG11201401665WA (en) 2014-09-26
CA2846568C (en) 2020-01-14
EP2776430B1 (en) 2016-03-16
SI2776430T1 (sl) 2016-06-30
CN103917538B (zh) 2016-08-24
UA112317C2 (uk) 2016-08-25
TWI555747B (zh) 2016-11-01
BR112014010617B1 (pt) 2021-12-14
AR088692A1 (es) 2014-06-25
MY167791A (en) 2018-09-26
NZ625896A (en) 2016-04-29
AU2012335194A1 (en) 2014-07-03
JP5718535B2 (ja) 2015-05-13
AU2012335194B2 (en) 2017-05-25
BR112014010617A8 (pt) 2017-12-26
EA024106B1 (ru) 2016-08-31
TW201323421A (zh) 2013-06-16
US9150566B2 (en) 2015-10-06
CN103917538A (zh) 2014-07-09
TWI565703B (zh) 2017-01-11
EA201400553A1 (ru) 2014-10-30
WO2013068935A1 (en) 2013-05-16
HRP20160678T1 (hr) 2016-07-15
KR101676930B1 (ko) 2016-11-16
MX2014005635A (es) 2014-06-23

Similar Documents

Publication Publication Date Title
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1125016T1 (el) Διαμορφωτες υποδοχεα πιπεριδινης cxcr7
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1119134T1 (el) Υποδοχεις της νεπριλυσινης
ATE483707T1 (de) 2-cyclopropylthiazolderivate
MD3468974T2 (ro) Noi derivați de piperidinil, procedeu pentru prepararea lor și compoziții farmaceutice care ii conțin
CY1120008T1 (el) Βενζαμιδια
MD3313850T2 (ro) Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin
NO20093200L (no) Tiazolidinderivater
CY1122196T1 (el) Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CY1119289T1 (el) Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου
CY1116004T1 (el) Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx
CY1121361T1 (el) Παραγωγα υδροξυαλκυλ πιπεραζινης ως ρυθμιστες υποδοχεα cxcr3
PH12015502632A1 (en) Cxcr7 receptor modulators
TN2016000061A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
UA112586C2 (uk) Похідні бензімідазолпроліну
CY1114642T1 (el) Παραγωγα αδαμαντυλο διαμιδιου και χρησεις αυτων
TH156808A (th) อนุพันธ์ 2-(1,2,3-ไทรอะซอล-2อิล)เบนซาไมด์ และ 3-(1,2,3-ไทรอะซอล-2-อิล)พิโคลินาไมด์